

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005261

International filing date: 16 December 2004 (16.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0329503.7
Filing date: 19 December 2003 (19.12.2003)

Date of receipt at the International Bureau: 09 February 2005 (09.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE

The Patent Office
 Concept House
 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Dated

10 January 2005

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1. Your reference	GHS/P504403GB		
2. Patent application number (The Patent Office will fill in this part)	0329503.7		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	SureScreen Diagnostics Limited 1 Prime Parkway Derby Derbyshire DE1 3QB		
Patents ADP number (if you know it)	7795701003		
If the applicant is a corporate body, give the country/state of its incorporation	United Kingdom		
4. Title of the invention	APPARATUS		
5. Name of your agent (if you have one)	W.P.THOMPSON & CO.		
“Address for service” in the United Kingdom to which all correspondence should be sent (including the postcode)	55 Drury Lane London WC2B 5SQ		
Patents ADP number (if you know it)	158007 ✓		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (Day/month/year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (Day/month/year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 9

Claims(s)

DL

Abstract

Drawing(s) 3+2

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(Please specify)

11. I/We request the grant of a patent on the basis of this application

Signature:

Date: 19 December 2003


W.P. THOMPSON & CO.

12. Name and daytime telephone number of person to contact in the United Kingdom SMAGGASGALE; Gillian, Helen
020 7240 2220

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

APPARATUS

The present invention relates to apparatus for use in testing the presence of foreign substances in a beverage. More particularly it relates to a test kit for detecting the presence of one or more 5 drugs in a beverage.

For ease of reference in the present application the term "drug" and "drugs" will be used to refer to any material which has been added to a beverage without the consent of the consumer. As will be explained in more detail below, the term will include alcohol, prescription pharmaceuticals, 10 over the counter pharmaceuticals, illegal substances and the like.

It has been known for many years for perpetrators wishing to cause harm to a victim to add a drug to the victim's beverage to alter the victim's behaviour or to incapacitate them totally. For example, alcohol may be added to a non-alcoholic drink or drugs may be added to either an 15 alcoholic or non-alcoholic drink. When the victim has drunk the beverage, their mood may be altered, or they may become totally incapacitated. While the victim is suffering from the effect of the drug the perpetrator may take advantage of the victim. In its mildest form, the victim's behaviour may simply be the source of amusement. Whilst this may be the perpetrator's intent, this can however have more serious consequences since the drug dose is generally unknown, as is 20 the effect of the combination of the drug with alcohol or any medical condition that the victim may have or any other medication they may be taking. Unfortunately, there is usually a more sinister intent such as robbery, rape or even murder.

Drugs currently commonly used include alcohol, drugs from the benzodiazapine family, gamma 25 hydroxybutyrate, 3,4-methylenedioxy-N-methylamphetamine (also known as MDMA or ecstacy), ketamines, cannabis and the like. Recent studies suggest that there are at least two hundred drugs available legally or illegally which could be secretly applied to beverages for the purpose of disabling or incapacitating the victim.

30 Of particular concern at the present time is the use of flunitrazepam which is a potent benzodiazapine drug sold under the trade name Rohypnol. Whilst this drug has legitimate uses,

It has become known as the "date rape" drug because of its use as an additive to beverages to cause the victim to become willing to any suggestion and being unable to remember the situation afterwards. It is therefore used to enable the perpetrator to obtain sex from the victim.

5 In an attempt to overcome this problem, the manufacturers of Rohypnol have added a blue dye to the prescription tablets to prevent them being added to drinks without the user being aware. However, there are still illicit forms of flunitrazepam available which are not coloured.

10 Drug rape usually goes unchecked since the victims are unable to remember the events or details and therefore are unreliable witnesses in any legal action. Even if the victim can remember some details or have suspicions they are often unwilling to come forward.

15 It is therefore desirable to provide a testing means which will enable users to test their beverage to establish whether it is safe to drink. The benefits of this system include that the user knows that he or she is safe and that where a drug is detected, there is a possibility that the perpetrator may be identified. Any such device could also be used by authorities to screen drinks at the scene of an alleged offence.

20 Whilst there are a variety of established technologies available for testing for drugs, these are generally based on laboratory or clinical tests and are therefore not suitable for use by the average consumer. They are also usually time consuming and expensive to run and require clean rooms and strict protocols to be observed. In addition, many of these systems are not able to function in the presence of an acid or alcohol and therefore have limited use in testing for drugs in beverages. These known tests also generally are only able to test for one drug at a time and require resetting 25 and recalibrating for the next drug to be tested.

30 Various proposals have been made to provide test apparatus which can be used at the site and time of consumption of the beverage. In US 6153147 a beverage analysis device is described in which a portion of liquid from the beverage can be captured and drawn into an analysis chamber where it is subjected to a chemical reagent composition and the results of the colour assay are viewed through a window.

In US 2001/0046710 a test strip, toothpick or cotton swab is described which can be immersed into the beverage and which will exhibit a colour change when gamma hydroxybutyrate is present in the beverage.

5

In GB 0217339.1 filed 26th July 2002 a test strip is described which is particularly useful for the detection of gamma hydroxybutyrate or methylene dioxymethamphetamine. The test strip may be replaced with a coaster having a plurality of testing means.

10 Whilst these arrangements go some way to providing a suitable solution to the desirability of providing a test which can be used at the point of consumption, it is still desirably to provide alternative, and preferably improved, arrangements and which preferably enable the user to test for one or more of a variety of drugs and which is preferably cost-effective to manufacture and easy to operate.

15

Thus according to the present invention there is provided a test kit for detecting the presence of one or more drugs in a beverage comprising a support having a plurality of detector strips releasably attached thereto.

20 In a preferred arrangement of the present invention the apparatus will contain detector strips for detecting the presence of at least two, and preferably at least three, different drugs. Thus the apparatus may include at least one strip for detecting the presence of benzodiazepines and at least one detector strip for testing for gamma hydroxy butyrate. It may also include at least one strip for detecting for the presence of alcohol.

25

In a further arrangement further strips may be included to test for one or more of ketamines, 3,4-methylenedioxy-N-methylamphetamine, cannabis, cocaine, barbiturates, opiates, tricyclic antidepreants, acetaminophen, propoxyphene and phencyclidine.

30 Whilst each detector strip may be configured to detect for more than one drug, in a preferred arrangement, each strip will test for one drug or one drug type only and will therefore be able to

be formed of the optimum material for testing for the particular drug.

In a particularly preferred arrangement the kit will include at least two of each type of drug detector strips.

5

The detector strip may be of any suitable configuration. It will generally be of elongate configuration but other suitable configurations may be used. The strip will comprise the detection means. The strip will comprise the detection means. The strip may be completely supplied as the detection means or may comprise a bed supporting the detection means. The 10 detection means will include assays or reagents which enable the target drug to be detected. For example, immunoassay, chemical spot, enzyme and the like techniques may be employed. For ease of reference, these will be collectively referred to as the "detection system". The material from the detection strip is constructed will depend on the detection system to be used. Where more than one detection system is used on different strips, they may be formed from different 15 materials.

Although the antibodies used in immunoassay techniques are often expensive and have poor tolerance to acids, alcohol, moisture and temperature extremes. However, immunoassay tests may be developed which are suitable for use in the present invention.

20

In one arrangement of the present invention a detector strip may be present which is suitable for the detection of the presence of benzodiazapines. In one arrangement this may be prepared using an immunoassay technique for example a lateral flow competitive immunoassay or lateral flow direct binding immunoassay. Full details of one example of this immunoassay technique can be 25 found in GB0217339 which is incorporated herein by reference.

In brief, a membrane is applied to the strip onto which is placed a pad of gold conjugate, bound to a first antibody having an affinity to the drug being tested, and a stripe, line or other indication from a second antibody is added which has an affinity for the first antibody. When the material 30 comes into contact with the beverage the liquid will travel along the membrane carrying the gold conjugate-antibody complex with it as it migrates. If a drug is present, it will bind to this

Complex and block any binding sites on the complex. As the complex passes the location of the second antibody, the gold conjugate, which is magenta in colour, does not bind and passes beyond the line, so that no colour change is observed. The failure to produce a colour change would notify the user that there was a drug present.

5

If no drug is present, the gold conjugate-antibody complex does not have its binding sites blocked and as it passes the stripe of the second antibody binding occurs and a coloured stripe, line or other indication is obtained.

10 In another embodiment the production of binding to give a visual signal may be obtained by means of a sandwich assay instead of lateral flow technology. In this embodiment the constituents already described are placed through a porous membrane and the reaction takes place through the sandwich, revealing the result as a spot, line or other indication in the absence of a drug in the benzodiazepines group. The technology may function either as a competitive
15 sandwich immunoassay or as a direct sandwich immunoassay.

Examples of suitable "other indications" include a tick or a cross or a suitable word such as "pass" or "OK".

20 Immunoassay techniques may also be utilized to provide detector strips which may be used to detect for the presence of ketamines, 3,4-methylenedioxy-N-methylamphetamine, cocaine, barbiturates, opiates, tricyclic antidepreeants, acetaminophen, propoxyphene and phencyclidine.

Whilst the detector strip for testing for benzodiazepines may be prepared using
25 immunodiagnostic technology, other techniques for example colour change chemistry may be used.

30 In the detector strips of the present invention, chemical spot techniques may be used as the detection means. Chemical spot tests rely on a reaction, such as a redox reaction, between the substance being tested and the chemical used to perform the reaction which changes colour either because it produces a complex or because there is an alkalinity/acidity/pH change. Usually there

is a colour change when the suspect drug is present. In one arrangement of the present invention the detector strip for detecting gamma hydroxybutyrate utilises chemical spot techniques.

In one embodiment of the present invention the test for gamma hydroxybutyrate operates by 5 applying a small spot of chemical indicator on a bed. Any suitable material may be used for the substrate including absorbent paper, cellulose sheet or film, cardboard or the like. The beverage is then brought into contact with the chemical indicator.

In one arrangement the detector strip for the detection of gamma hydroxybutyrate may be in the 10 form of an elongate bed with a small area impregnated with the chemical indicator material. In an alternative embodiment the detector strip may be absorbent paper impregnated with the chemical indicator material.

In one arrangement of this latter embodiment the detector strip comprises a strip of absorbent 15 paper impregnated with ferrous chloride in a buffer. When this strip is brought into contact with a beverage containing gamma hydroxybutyrate the ferrous chloride is oxidised to ferric chloride by the presence of the gamma hydroxybutyrate.

In another embodiment the chemical will react to pH change. This is possible since gamma 20 hydroxybutyrate is generally a clandestine product derived from butyrolactone solvent with caustic, and is left in mildly alkaline form. Its addition to beverages will change the alkalinity of the beverage. This is readily detectable using the proposed chemical formulation. When there is typically 1 mg or more of gamma hydroxybutyrate in the beverage, the strip will turn blue when it comes into contact with the beverage.

25

This chemical spotting technology may also be used to provide a detection strip for use in the detection of amphetamines both pharmaceutical grade amphetamines and also those from 'street drugs' samples or clandestine tablets. In addition, it may be used to detect the presence of ketamines. Where X (**what is the material impregnated in Paper B?**) is impregnated in the 30 absorbent material, it will produce a reddish colour when amphetamines are present or pink if ketamine is present. In addition, it will produce blackened speckles and tiny red/orange intense

speckles when benzodiazepine is present. The blackened speckles are produced by the presence of bulking agents in the tablet and the red/orange intense speckles are due to the presence of the active benzodiazepine.

- 5 When aqueous solutions are applied to material impregnated with X blackening will occur although this blackening reduces where the solution is acidic. Thus in one arrangement in which X is used in the detection strip, an acidic salt may be incorporated in the paper to minimise this effect when the strip is brought into contact with beverages.
- 10 Alcohol may be detected by an enzyme-based reaction in which chemical changes occur, leading to a colour change.

The support to which the detection strips are releasably attached may be formed of any suitable materials. Suitable materials include those which are lightweight and have sufficient inherent strength not to become crushed in use and include cardboard and plastics material. The support material may be of any suitable configuration. Whilst it will generally be rectangular any shape may be used.

The detection strips may be attached to the support by any suitable means. In one arrangement at least a portion of the detection strip may be formed integrally with the support and may be connected thereto by a frangible flange. Thus in use the detection strip may be removed from the apparatus by breaking the detection strip from the support.

In an alternative arrangement, the detection strips may be attached to the support by means of an adhesive. Any suitable adhesive may be used. In use the desired strip can be removed from the support by means of breaking the adhesive bond. In an alternative arrangement the detection strip may be removed from the support by breaking the strip above the point where it is attached to the support by means of the adhesive. For example where the detection strip is made of impregnated paper or has a cardboard base it may simply be torn from the support. However, where the detection strip has for example a plastics support, it may be provided with an area of weakness where it can be split off. In an alternative arrangement, the adhesive may be a weak

adhesive which will allow the detection strip to be removed from the support by, for example, peeling.

The test apparatus of the present invention may be of any suitable configuration. In one 5 arrangement, the strips may extend from the support in a finger-like arrangement. However, in a more preferred arrangement, the strips will be laid across the face of the support.

In a most preferred arrangement, the apparatus will include a cover for the support to protect the 10 detection strips when they are not in use. The cover may be a wallet or box into which the support may be placed. In an alternative arrangement, the cover is integral with the support. Thus in one arrangement the support may be sized such that it may be folded into two parts such that when "closed" a first part may be laid over the strips which are attached to the second part. In use, the first part will be folded back to reveal the strips.

15 In another arrangement, there may be a third part which at least partially folds over the first part when it is in closed position to help hold it in position.

Thus in one particularly preferred arrangement, the apparatus of the present invention will be 20 configured to resemble a match book. The overall size of the kit when closed may be similar to a conventional match book or may be of the size of a business card.

Where the support is made from non-plastics material such as of cardboard, it may be coated on one or both surfaces with a water-resistant coating to provide protection.

25 The support may also be printed with instructions for use and/or advice and/or guidance relating to drugs. Advertising material may also be present.

Thus a particular benefit of the present invention is that the user has a discrete kit providing them with a wide range of testing options and which is simple to use and operate.

30

Various modifications of the apparatus may be provided. Since it is often dark in venues, the

apparatus may include means to enable the user to find the appropriate strip, such as raised portions on the stick shaped to correspond to the drug to be tested. Additionally or alternatively, fluorescent markings may be used or a small light device may be included.

5 The present invention will now be described, by way of example, with reference to the accompanying drawings:

Figure 1 illustrates one arrangement of the present invention;

10 Figure 2 illustrates a second arrangement of the present invention;

Figure 3 illustrates a still further arrangement of the present invention; and

Figure 4 illustrates a product of the present invention.

15 As illustrated in Figure 1, the first arrangement of the present invention comprises a support 1 and a plurality of tear off detection strips 2.

20 Figure 2 illustrates a second arrangement where the detector strips 2 are attached by means of an adhesive to a face of the support 1.

Figure 3 illustrates a preferred arrangement where the detector strips 2 are located on the face of a support 1. The support has folds 3a and 3b which enables it to be folded over the strips to protect the strips. An example of the product is shown in Figure 4.



1/3




Figure 1




Figure 2



2/3




Figure 3



3/3

